Effectiveness of Granulocyte Colony-Stimulating Factor in Hospitalized Infants with Neutropenia

Area of Science:

• Neonatal Medicine
• Pediatric Hematology
• Pharmacology

Background:

• Neutropenia in infants is a critical condition requiring careful management.
• Granulocyte colony-stimulating factor (G-CSF) is used to increase neutrophil counts.
• The safety and efficacy of G-CSF in neonatal neutropenia require further investigation.

Purpose of the Study:

• To evaluate the impact of G-CSF on hematologic recovery time in neutropenic infants.
• To assess the incidence of secondary sepsis and mortality in G-CSF treated versus untreated neutropenic infants.
• To determine the safety profile of G-CSF in this vulnerable population.

Main Methods:

• Retrospective cohort study of 30,705 neutropenic infants from 1997-2012.
• Neutropenia defined as absolute neutrophil count ≤1,500/µL for ≥1 day within the first 120 days of life.
• Comparison of hematologic recovery, sepsis, and mortality rates between G-CSF exposed and unexposed infants.

Main Results:

• G-CSF treated infants (7%) showed a shorter time to hematologic recovery (HR: 1.36).
• G-CSF treatment was associated with higher adjusted odds of secondary sepsis (OR: 1.50) and death (OR: 1.33).
• Increased odds of combined sepsis or death outcome were observed in G-CSF treated infants (OR: 1.41) persisting at day 28.

Conclusions:

• G-CSF accelerates hematologic recovery in neutropenic infants.
• G-CSF treatment is linked to increased risks of secondary sepsis and mortality.
• Routine use of G-CSF for neonatal neutropenia is not supported by these findings.